Corporation
Johnson & Johnson (Canada) Inc.
- Meetings this Parliament
- 15
- With MPs
- 5
- Since Nov 2021
- 42
- Active registrations
- 1
Most recent reported meeting: Feb 17, 2026.
Lobbying by Johnson & Johnson (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 18, 2026
Filed by Robbie Levac, General Manager
Lobbyists
- Julie Bergeron · National Director, Key Accounts Team
- Robbie Levac · General Manager
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (17)Hide details
- Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity.
- Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
- Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
- Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
- Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
- Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
- Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
- Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
- Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
- Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
- Food and Drugs Act: Delays in product approvals and changes to existing products.
- COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
- Communication to officials on labelling and product monographs.
- Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
- Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
- Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
- Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
Registration 964083-373927-11. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by James Brodie (37), Robbie Levac (5).
-
Reported by Robbie Levac · In-house (corporation)
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada Read more
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
-
Reported by Robbie Levac · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Privy Council Office (PCO)
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies. Read more
-
Reported by Robbie Levac · In-house (corporation)
- Paul Hebert · President, Canadian Institutes of Health Research (CIHR)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by Robbie Levac · In-house (corporation)
- Maggie Chi · Parliamentary Secretary to the Minister of Health, Health Canada (HC)
- Nora Draper · Assistant to Parliamentary Secretary Maggie Chi, Health Canada (HC)
- Justine Frame · Policy Advisor, Minister’s Office, Health Canada (HC)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Read more
-
Reported by Robbie Levac · In-house (corporation)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Elizabeth Wong · Policy Advisor, Minister’s Office, Health Canada (HC)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Read more
-
Reported by James Brodie · In-house (corporation)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff to the Minister of Health, Health Canada (HC)
Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity. Read more
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
-
Reported by James Brodie · In-house (corporation)
- Evan Solomon · Minister of Artificial Intelligence and Digital Innovation, Innovation, Science and Economic Development Canada (ISED)
Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity. Read more
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
-
Reported by James Brodie · In-house (corporation)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity. Read more
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
- Paul Hebert · Chief Executive Officer, Canadian Institutes of Health Research (CIHR)
- Jeff Moore · Associate Vice President, Government and External Relations, Canadian Institutes of Health Research (CIHR)
Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity.
-
Reported by James Brodie · In-house (corporation)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Sarah Lawley · Assistant Deputy Minister, Health Policy Branch, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Products and Food Branch, Health Canada (HC)
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Read more
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Mark Schaan · Associate Deputy Minister for Artificial Intelligence and Digital Innovation, Innovation, Science and Economic Development Canada (ISED)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Read more
-
Reported by James Brodie · In-house (corporation)
- Paul Moen · Chief of Staff to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Read more
-
Reported by James Brodie · In-house (corporation)
- Karim Bardeesy · Member of Parliament
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics. Read more
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Interim Head, Health Emergency Readiness Canada (HERC), Innovation, Science and Economic Development Canada (ISED)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada. Read more
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada. Read more
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Heather Jeffrey · President, Public Health Agency of Canada (PHAC)
- Cindy Evans · Vice President, Public Health Agency of Canada (PHAC)
HealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.